Evidence map›Paper›PMID 31941780›Full record

ArticleJournal of virology2020

Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.

Eri Miyagi, Sarah Welbourn, Sayaka Sukegawa, Helena Fabryova, Sandra Kao, Klaus Strebel

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eri MiyagiLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Sarah WelbournLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Sayaka SukegawaLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Helena FabryovaLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Sandra KaoLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Klaus StrebelLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA kstrebel@nih.gov.
National Institute of Allergy and Infectious Diseases · US

Funding

Molecular Analysis Of Retroviral Genes And Their ProductsZIAAI000669 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI STREBEL, KLAUS · 2009 to 2025
$25.2M
Molecular Analysis Of Retroviral Genes &Their ProductsZ01AI000669 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI STREBEL, KLAUS · 1993 to 2008
$852k
Intramural NIH HHS Z01 AI000669
6 · The paper itself

Abstract

Vif counteracts the host restriction factor APOBEC3G (A3G) and other APOBEC3s by preventing the incorporation of A3G into progeny virions. We previously identified Vif mutants with a dominant-negative (D/N) phenotype that interfered with the function of wild-type Vif, inhibited the degradation of A3G, and reduced the infectivity of viral particles by increased packaging of A3G. However, the mechanism of interference remained unclear, in particular since all D/N Vif mutants were unable to bind Cul5 and some mutants additionally failed to bind A3G, ruling out competitive binding to A3G or the E3 ubiquitin ligase complex as the sole mechanism. The goal of the current study was to revisit the mechanism of D/N interference by Vif mutants and analyze the possible involvement of core binding factor beta (CBFβ) in this process. We found a clear correlation of D/N properties of Vif mutants with their ability to engage CBFβ. Only mutants that retained the ability to bind CBFβ exhibited the D/N phenotype. Competition studies revealed that D/N Vif mutants directly interfered with the association of CBFβ and wild-type Vif. Furthermore, overexpression of CBFβ counteracted the interference of D/N Vif mutants with A3G degradation by wild-type Vif. Finally, overexpression of Runx1 mimicked the effect of D/N Vif mutants and inhibited the degradation of A3G by wild-type Vif. Taken together, we identified CBFβ as the key player involved in D/N interference by Vif.

Indexed as

APOBEC-3G DeaminaseBinding, CompetitiveCore Binding Factor Alpha 2 SubunitCore Binding Factor beta SubunitCullin ProteinsElonginGenes, DominantHEK293 CellsHIV-1HumansLeukocytes, MononuclearMutationPhenotypevif Gene Products, Human Immunodeficiency VirusVirionAPOBEC-3G DeaminaseAPOBEC3G protein, humanCBFB protein, humanCore Binding Factor Alpha 2 SubunitCore Binding Factor beta SubunitCUL5 protein, humanCullin ProteinsELOB protein, humanElonginRUNX1 protein, humanvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1APOBEC3GCBFβdominant-negativeinterferenceVif

Identifiers

PMID31941780
PMCPMC7081906
OpenAlexW2998760640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.